Nothing Special   »   [go: up one dir, main page]

BRPI0514982A - adjuvante de glicosilceramida para antìgenos de sacarìdeo - Google Patents

adjuvante de glicosilceramida para antìgenos de sacarìdeo

Info

Publication number
BRPI0514982A
BRPI0514982A BRPI0514982-7A BRPI0514982A BRPI0514982A BR PI0514982 A BRPI0514982 A BR PI0514982A BR PI0514982 A BRPI0514982 A BR PI0514982A BR PI0514982 A BRPI0514982 A BR PI0514982A
Authority
BR
Brazil
Prior art keywords
saccharide
glycosylceramide adjuvant
saccharide antigens
glycosylceramide
adjuvant
Prior art date
Application number
BRPI0514982-7A
Other languages
English (en)
Inventor
Grazia Galli
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0514982A publication Critical patent/BRPI0514982A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ADJUVANTE DE GLICOSILCERAMIDA PARA ANTìGENOS DE SACARìDEO A invenção fornece composições e kits que compreendem: (a) um conjugado de antígeno sacarídeo a um veículo; e (b) um adjuvante de <244>-glicosilceramida. A invenção também fornece métodos de tratamento que emprega as composições. Descobriu-se que a supressão de respostas imunes anti-sacarídeo por <244>-glicosilceramidas pode ser revertida por conjugação do sacarídeo a um veículo.
BRPI0514982-7A 2004-09-07 2005-09-07 adjuvante de glicosilceramida para antìgenos de sacarìdeo BRPI0514982A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419846.1A GB0419846D0 (en) 2004-09-07 2004-09-07 Vaccine adjuvants for saccharides
PCT/IB2005/002788 WO2006027685A2 (en) 2004-09-07 2005-09-07 Glycosylceramide adjuvant for saccharide antigens

Publications (1)

Publication Number Publication Date
BRPI0514982A true BRPI0514982A (pt) 2008-07-01

Family

ID=33186601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514982-7A BRPI0514982A (pt) 2004-09-07 2005-09-07 adjuvante de glicosilceramida para antìgenos de sacarìdeo

Country Status (11)

Country Link
US (1) US8790654B2 (pt)
EP (1) EP1789059A2 (pt)
JP (1) JP5038136B2 (pt)
CN (2) CN102319428A (pt)
AU (1) AU2005281421B2 (pt)
BR (1) BRPI0514982A (pt)
CA (1) CA2579488C (pt)
GB (1) GB0419846D0 (pt)
MX (1) MX2007002787A (pt)
RU (2) RU2007112794A (pt)
WO (1) WO2006027685A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
EP1897557A1 (en) 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2748819A1 (en) * 2009-01-08 2010-07-15 Steven A. Porcelli Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
WO2010133609A2 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SG10201911003QA (en) 2012-03-09 2020-01-30 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013178236A1 (en) * 2012-05-26 2013-12-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Carbohydrate-glycolipid conjugate vaccines
KR101675657B1 (ko) * 2012-03-19 2016-11-11 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 탄수화물-당지질 컨쥬게이트 백신
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
JP6143240B2 (ja) * 2013-05-02 2017-06-07 国立研究開発法人産業技術総合研究所 糖鎖抗原の免疫誘導剤
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
EP2851092A1 (en) 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
DK3215127T3 (da) 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
GB201818517D0 (en) * 2018-11-13 2018-12-26 Univ Liverpool John Moores Nanoparticles and uses thereof
WO2021115408A1 (zh) * 2019-12-13 2021-06-17 南京远大赛威信生物医药有限公司 药物组合物及其用途
CN111249451B (zh) * 2020-01-20 2022-11-04 成都医学院 一种糖脂类抗原注射液及其制备方法
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
NZ622900A (en) * 2001-01-23 2015-11-27 Sanofi Pasteur Inc Multivalent meningococcal polysaccharide-protein conjugate vaccine
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2493690C (en) * 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1663303B1 (en) 2003-09-15 2011-05-04 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus agalactiae
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2577009C (en) 2004-08-27 2017-05-02 Steven A. Porcelli Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation

Also Published As

Publication number Publication date
JP2008512371A (ja) 2008-04-24
RU2011131658A (ru) 2013-02-10
AU2005281421B2 (en) 2011-09-22
AU2005281421A1 (en) 2006-03-16
GB0419846D0 (en) 2004-10-13
CA2579488C (en) 2015-01-20
US20080199487A1 (en) 2008-08-21
MX2007002787A (es) 2007-05-18
CA2579488A1 (en) 2006-03-16
CN102319428A (zh) 2012-01-18
RU2007112794A (ru) 2008-10-27
CN101035546A (zh) 2007-09-12
JP5038136B2 (ja) 2012-10-03
US8790654B2 (en) 2014-07-29
WO2006027685A3 (en) 2006-05-11
WO2006027685A2 (en) 2006-03-16
EP1789059A2 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
BRPI0514982A (pt) adjuvante de glicosilceramida para antìgenos de sacarìdeo
UA92505C2 (ru) Композиции на основе антитела против cd3
JO3000B1 (ar) مركبات أجسام مضادة .
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
BRPI0519232A2 (pt) vacinas de conjugados de sacarÍdeos
MX2009008140A (es) Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
BRPI0619357B8 (pt) anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
EA200702577A1 (ru) Способ изготовления вакцин
WO2007067681A3 (en) Immunostimulatory compositions and methods
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200702180A1 (ru) Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4
WO2006102395A3 (en) Delivery systems and methods for diagnosing and treating cardiovascular diseases
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
EA200600646A1 (ru) Способы, наборы и композиции для разработки и применения моноклональных антител, специфичных к антигенам с низкой иммуногенностью
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
CY1112149T1 (el) Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο
WO2007053781A3 (en) Compositions with antigens adsorbed to calcium phosphate
WO2021257695A8 (en) Methods and compositions related to neutralizing antibodies against human coronavirus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/7032 (2006.01), A61K 39/39 (2006.01), A61K